Price history
¥11,170Latest+208.6%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 20
PER
54.5How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
0.8How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
1.5%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥33bnShare price × number of shares. The value of the entire company.Equity ratio
57.0%The proportion of assets funded by money that does not have to be repaid.Operating margin
7.3%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
0.1%The average annual growth in sales over the past three years.What to watch next
Launch and execution of the new medium-term management plan (2026-2028), including disclosure of progress toward the 7% ROE target
FY2026 onward (the first year of the plan)Impact HighLikelihood Medium
Progress in improving productivity in the collagen casing business, including narrowing the product range, reviewing processes, optimizing inventory and disposing of unprofitable equipment, as well as whether further impairment losses occur
To be assessed during the quarters and full year of FY2026Impact HighLikelihood Medium
Realization of the ¥1,387 million dividend expected to be received following the subsidiary's capital reduction scheduled for 18 December 2025, and its subsequent impact on capital efficiency and investment capacity
December 2025 (scheduled), with the accounting impact reflected in the fiscal year ending March 2026Impact MediumLikelihood High
Life sciences: sales progress for new laminin-containing products launched in October 2024, as well as progress in external adoption and joint development related to spERt, MatriMix and iMatrix
FY2026, with sales and contract information disclosed as it becomes availableImpact MediumLikelihood Medium
Building functional evidence for oral consumption and compliance with the Foods with Function Claims system, including filings, acceptance and progress on supporting evidence
From fiscal 2026 onwardImpact MediumLikelihood Low
What to watch next
Who owns itTop holders total 42.7%
Listed holders 42.7%Everyone else 57.3%
リーガルコーポレーション12.70%
TAISEI CORPORATION7.95%
中央建物株式会社4.16%
Tokyo Tatemono Co.,Ltd.3.57%
石橋拓朗3.39%
Naito Seigo (内藤征吾)3.04%
Mizuho Bank2.49%
Mizuho Trust & Banking Co., Ltd.2.14%
2 other listed holders3.29%
| Holder | Ownership (%) |
|---|---|
| リーガルコーポレーション | 12.70 |
| TAISEI CORPORATION | 7.95 |
| 中央建物株式会社 | 4.16 |
| Tokyo Tatemono Co.,Ltd. | 3.57 |
| 石橋拓朗 | 3.39 |
| Naito Seigo (内藤征吾) | 3.04 |
| Mizuho Bank | 2.49 |
| Mizuho Trust & Banking Co., Ltd. | 2.14 |
| 2 other listed holders | 3.29 |
This company's documents
Filings
Timely disclosures
- 2026-08-07Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)
- 2026-06-02Notice of Convocation of the 2026 Annual General Meeting of Shareholders
- 2026-06-01Notice of Independent Officer Status
- 2026-05-22Notice Regarding Personnel Changes
- 2026-05-15Status of Membership in the Financial Accounting Standards Foundation and Other Information
- 2026-05-15Notice Regarding Dividend from Retained Earnings
- 2026-05-15Notice Regarding Differences Between Individual Financial Results and Results for the Previous Fiscal Year
- 2026-05-15Financial Results for the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated)